(S027) Patterns of Failure for Rhabdomyosarcoma of the Perineal and Perianal Region

Publication
Article
OncologyOncology Vol 28 No 4_Suppl_1
Volume 28
Issue 4_Suppl_1

Purpose: Rhabdomyosarcoma of the perineal and perianal region (PRMS) has poor outcomes. We analyzed prognostic factors and patterns of failure, with an emphasis on radiotherapy for locoregional control.

Dana L. Casey, Leonard H. Wexler, MD, Michael P. LaQuaglia, MD, Paul A. Meyers, MD, Suzanne L. Wolden, MD, FACR; Memorial Sloan-Kettering Cancer Center

Purpose: Rhabdomyosarcoma of the perineal and perianal region (PRMS) has poor outcomes. We analyzed prognostic factors and patterns of failure, with an emphasis on radiotherapy for locoregional control.

Materials and Methods: Detailed records of all 15 patients treated for PRMS at Memorial Sloan-Kettering between 1998 and 2012 were reviewed. The Kaplan-Meier method was used to assess event-free survival (EFS) and overall survival (OS), and a competing-risks analysis was used to assess the cumulative incidence of local, regional, and distant failures.

Results: Median age was 15.1 years (range: 0.9–31.9 yr). High-risk features were identified: 73% of the patients had group III disease and 20% had group IV; 67% of tumors were alveolar; 87% of tumors were ≥ 5 cm; and 67% of patients had involved lymph nodes (N1). Of those aged ≥ 10 years at diagnosis, 89% had alveolar histology, 100% had tumors ≥ 5 cm, and 78% presented with N1 disease. The rates of local, regional, and distant failure at 5 years were 16%, 36%, and 35%, respectively. Although four of the five patients with regional failure received nodal irradiation, only one of the nodal failures occurred in the radiotherapy field. The 5-year EFS was 42%, and OS was 56%. Age ≥ 10 years was associated with poor outcomes: EFS was 15% in patients aged ≥ 10 years compared with 67% in those aged < 10 years (P = .04); the OS was 22% in patients aged ≥ 10 years compared with 100% in those aged < 10 years (P = .05).

Conclusions: Patients with PRMS, especially those aged ≥ 10 years, present with poor prognostic features and continue to have poor outcomes. Given the high incidence of regional node recurrence, we recommend prophylactic ilioinguinal lymph node irradiation for all patients aged ≥ 10 years. For children aged < 10 years, surgical evaluation of the ilioinguinal lymph nodes to determine the role for nodal irradiation is appropriate.

Proceedings of the 96th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Soft Tissue Sarcoma Metastases
(S001) Limb-Sparing Surgery and Intraoperative Radiotherapy in the Treatment of Primary, Nonmetastatic Extremity and Limb-Girdle Soft Tissue Sarcoma
(S003) Disparities in Stage at Diagnosis and Survival in Adult Cancer Patients According to Insurance Status
(S004) Radiation Publications Underrepresented in High-Impact General Medical and Oncology Journals 
(S005) Adjuvant Radiotherapy in Stage II Endometrial Carcinoma: Is Brachytherapy Alone Sufficient for Local Control?
(S006) Extended-Field IMRT With Concomitant Boost for Node-Positive Cervical Cancer: Analysis of Regional Control Rate and Recurrence Pattern
(S007) Stereotactic Radiosurgery to the Brain With Concurrent BRAF Inhibitors for Melanoma Metastases
(S008) Use of Mobile Devices for Creation of Survivorship Care Plans
(S009) Two-Year Outcomes Following Triapine Radiochemotherapy for Cervical Cancer 
(S010) Prospective and Real-Time Data Analysis of Image-Guided Radiotherapy Across a Multinational Pediatrics Consortium: Methodology and Considerations 
(S011) Comparison of Toxicities and Outcomes for Conventional and Hypofractionated Radiation Therapy for Early Glottic Carcinoma
(S013) Adjuvant Radiation Therapy and Temozolomide for Anaplastic Gliomas: The Twelve-Year Washington University Experience
(S014) Gamma Knife Stereotactic Radiosurgery in the Treatment of Brainstem Metastases
(S015) Temporal Lobe Radionecrosis After Skull Base Radiotherapy: Dose-Volume Predictors 
(S012) Prognostic Value of Radiographic Extracapsular Extension in Locally Advanced Non-Oropharyngeal Head and Neck Squamous Cell Cancers
Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Related Content